In the parent trial, PZ supplements and MNP reduced the prevalence of zinc deficiency, and MNP reduced the prevalence of iron deficiency, indicating that the population was responsive to nutritional supplementation.28 However, there were no overall treatment effects on linear growth or morbidity.28,49 In addition, there was no overall impact on markers of intestinal inflammation (neopterin, myeloperoxidase, and calprotectin) among children participating in a separate sub-study of the parent trial,50 also suggesting that the intervention may not have affected EED. The gene discussed is MPO; the disease is Zinc deficiency.